Get the Stockscreener App
12.32
0.00%
0.00
After Hours:
12.50
0.18
+1.46%
Ocular Therapeutix Inc stock is traded at $12.32, with a volume of 1.99M.
It is up +0.00% in the last 24 hours and up +0.90% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$12.32
Open:
$12.19
24h Volume:
1.99M
Relative Volume:
0.85
Market Cap:
$2.14B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-9.1259
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
+3.01%
1M Performance:
+0.90%
6M Performance:
+77.52%
1Y Performance:
+36.28%
1-Day Range:
$12.19
$12.46
1-Week Range:
$11.82
$12.49
52-Week Range:
$5.80
$12.91
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
12.32 | 2.14B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Ocular Therapeutix Executives Engage in Stock Transactions - TradingView
Statistical indicators supporting Ocular Therapeutix Inc.’s strengthJuly 2025 WrapUp & Reliable Entry Point Trade Alerts - Newser
Ocular Therapeutix Inc. stock trend outlook and recovery path2025 Price Momentum & Low Risk Entry Point Guides - Newser
Ocular Therapeutix Inc. stock retracement – recovery analysis2025 Analyst Calls & Safe Entry Point Identification - Newser
How hedge fund analytics apply to Ocular Therapeutix Inc. stockDividend Hike & Real-Time Stock Entry Alerts - Newser
Has Ocular Therapeutix Inc. found a price floorMarket Trend Report & Capital Efficiency Focused Strategies - Newser
Is Ocular Therapeutix Inc. stock poised for growthBull Run & Low Drawdown Trading Strategies - Newser
Does Ocular Therapeutix Inc. fit your quant trading modelGap Down & Detailed Earnings Play Alerts - Newser
Retina Treatment Innovation: Ocular Therapeutix to Showcase OTX-TKI Data at 5 Major Medical Conferences - Stock Titan
News impact scoring models applied to Ocular Therapeutix Inc.2025 Retail Activity & Long-Term Safe Investment Plans - Newser
Ocular Therapeutix Drops 10.71% on Earnings Miss - AInvest
Visual trend scoring systems applied to Ocular Therapeutix Inc.Gap Down & Expert Approved Trade Ideas - Newser
Historical volatility pattern of Ocular Therapeutix Inc. visualizedShort Setup & Weekly Chart Analysis and Guides - Newser
Is it time to cut losses on Ocular Therapeutix Inc.Earnings Beat & Technical Buy Zone Confirmation - Newser
Best data tools to analyze Ocular Therapeutix Inc. stockJuly 2025 Momentum & Fast Gain Swing Alerts - Newser
Chart based analysis of Ocular Therapeutix Inc. trendsJuly 2025 Highlights & AI Forecast Swing Trade Picks - Newser
What high frequency data says about Ocular Therapeutix Inc.July 2025 Final Week & Capital Protection Trading Alerts - Newser
Quantitative breakdown of Ocular Therapeutix Inc. recent moveShare Buyback & Consistent Return Strategy Ideas - Newser
Ocular Therapeutix Inc. Rebound Backed by Sentiment Shift2025 Fundamental Recap & Free Accurate Trade Setup Notifications - classian.co.kr
What are Ocular Therapeutix Inc.’s earnings expectationsJuly 2025 Retail & AI Enhanced Trading Signals - theviewers.co.kr
Using Bollinger Bands to evaluate Ocular Therapeutix Inc.July 2025 Breakouts & Real-Time Volume Analysis - Newser
Is There Enough Volume to Lift Ocular Therapeutix Inc.Market Trend Summary & Precise Buy Zone Identification - 더경남뉴스
Backtesting results for Ocular Therapeutix Inc. trading strategiesWeekly Trade Analysis & High Accuracy Investment Entry Signals - Newser
Ocular Therapeutix Inc. Shows Support at Fibonacci LevelJuly 2025 Outlook & Weekly High Conviction Ideas - newsyoung.net
Ocular Therapeutix Inc. Stock Poised for Technical ComebackJuly 2025 Closing Moves & Weekly Top Stock Performers List - mustnews.co.kr
Is Ocular Therapeutix Inc. stock bottoming outTrade Risk Report & Community Consensus Stock Picks - Newser
Can swing trading help recover from Ocular Therapeutix Inc. lossesStock Surge & AI Driven Price Predictions - Newser
Has Ocular Therapeutix Inc. Stock Ever Crashed Historical Volatility ReviewMarket Activity Summary & Fast Moving Market Watchlists - Newser
What makes Ocular Therapeutix Inc. stock price move sharply2025 Price Momentum & Breakout Confirmation Alerts - Newser
Using data filters to optimize entry into Ocular Therapeutix Inc.Portfolio Return Report & Low Drawdown Trading Strategies - Newser
Ocular gets FDA agreement for registrational trial of Axpaxl - MSN
Quant Strategy Flags Ocular Therapeutix Inc. for EntryJuly 2025 Earnings & Community Consensus Picks - newsyoung.net
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript - MSN
What earnings revisions data tells us about Ocular Therapeutix Inc.July 2025 Drop Watch & Community Shared Stock Ideas - Newser
Momentum divergence signals in Ocular Therapeutix Inc. chartPortfolio Return Report & Weekly High Conviction Trade Ideas - Newser
Ocular Therapeutix receives FDA agreement under SPA for registrational trial of AXPAXLI in NPDR - Eyes On Eyecare
FDA agrees to SPA for Ocular Therapeutix NPDR registrational trial - Eyes On Eyecare
Ocular Therapeutix at H.C. Wainwright: Strategic Moves in Eye Care By Investing.com - Investing.com Canada
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):